|
PMID
|
Match String
|
Actual String
|
Score
|
Flanking text
|
Edited by
|
Edit
|
| 11173059 | EAAT2 | EAAT-2 | 0.3 | transporters have already been cloned the glial transporters EAAT-1 and EAAT-2 and the neuronal transporters EAAT-3 EAAT-4 and EAAT-5 (the the | |  |
| 11173059 | EAAT2 | EAAT-2 | 0.3 | originates from a decreased expression of the glial glutamate transporter EAAT-2 ( Rothstein et al. 1995 | | |
| 11173059 | EAAT2 | EAAT-2 | 0.3 | The loss of EAAT-2 is not related to genomic mutations and selective EAAT 2 | | |
| 11173059 | EAAT2 | EAAT-2 | 0.3 | Alternatively EAAT-2 deficiency could derive from defective translational or post-translational mechanisms secondary | | |
| 15210305 | EAAT2 | EAAT2 | 1.3 | receptors and of the excitatory amino acid transporter 2 (EAAT2) EAAT2 (which which is involved in the removal of glutamate from | | |
| 15210305 | EAAT2 | EAAT2 | 1.3 | expression studies have highlighted the early focal loss of the EAAT2 glutamate transporter in the ventral horn of the G93A TG | | |
| 15210305 | EAAT2 | EAAT2 | 1.3 | pattern of steady increase of gliosis paralleled with a 90% EAAT2 loss in the ventral horn is also reported suggesting a | | |
| 15572176 | EAAT2 | EAAT2 | 2.8 | (COX-2), COX-2 display nitrotyrosine immunoreactivity and downregulate the glutamate transporter EAAT2 | | |
| 15572176 | GLT-1 | GLT-1 | 2.8 | of SOD1-containing aggregates and decreased expression of glial glutamate transporter GLT-1 18 | | |
| 15572176 | GLT-1 | GLT-1 | 2.8 | the neuropil and with a striking focal loss of the GLT-1 glutamate transporter in the ventral horn | | |
| 15572176 | EAAT2 | EAAT2 | 2.8 | fluid and a selective reduction of the astrocytic glutamate transporter EAAT2 (GLT1), GLT1 giving support to the excitotoxic hypothesis of motor | | |
| 15572176 | GLT1 | GLT1 | 2.8 | a selective reduction of the astrocytic glutamate transporter EAAT2 (GLT1), GLT1 giving support to the excitotoxic hypothesis of motor neuron degeneration | | |
| 15572176 | EAAT2 | EAAT2 | 2.8 | In patients with ALS EAAT2 transporters are decreased or defective 108 and 114 which is | | |
| 15572176 | EAAT2 | EAAT2 | 2.8 | Significant loss of the EAAT2 transporters has also been documented in the spinal cord of | | |
| 15572176 | EAAT2 | EAAT2 | 2.8 | In contrast neither EAAT1 nor EAAT2 transporters seem to be affected in presymptomatic or symptomatic mice | | |
| 15572176 | EAAT2 | EAAT2 | 2.8 | The presence of aberrant mRNA splice variants for EAAT2 in ALS has been hypothesized as a putative cause of | | |
| 15572176 | EAAT2 | EAAT2 | 2.8 | in ALS has been hypothesized as a putative cause of EAAT2 loss 6 and 79 | | |
| 16179515 | EAAT2 | EAAT2 | 1.0 | stroma-derived factor-1 (SDF-1), SDF-1 and excitatory amino acid transporter-2 (EAAT2) EAAT2 | | |
| 16624536 | EAAT2 | EAAT2 | 1.0 | been observed to have decreased expression of the glutamate transporter EAAT2 potentially leading to decreased glutamate transport and subsequent increases in | | |
| 16624536 | EAAT2 | EAAT2 | 1.0 | this decrease in expression resulting from alternately spliced variants of EAAT2 has been demonstrated in normal controls in addition to ALS | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | that PDTC treatment prevented the reduction of the glutamate transporter GLT-1 a potential therapeutic target verified in numerous animal studies of | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | in models of ALS by increasing expression of glutamate transporter GLT-1 (Rothstein Rothstein et al. 2005 beta-lactams because it significantly increases | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | al. 2005 beta-lactams because it significantly increases the expression of GLT-1 and Cu concentration in the spinal cord We hypothesize that | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | though beta-lactams and PDTC might both be able to modulate GLT-1 and Cu concentration only PDTC but not beta-lactams inhibits immunoproteasome | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | as an antioxidant and activating Akt-GSK3 beta pathway also induces GLT-1 a potential drug target in brain diseases | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | PDTC led to decreased immunoproteasome levels and increased GLT-1 levels in TG rats at the end stage whereas PDTC | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | no effect on the levels of constitutive proteasome immunoproteasome or GLT-1 in WT rats | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | effect on the levels of astrocyte specific glutamate transporter (GLT-1) GLT-1 | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | the spinal cords of untreated TG rats the levels of GLT-1 were decreased whereas in PDTC-treated TG rats the levels of | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | were decreased whereas in PDTC-treated TG rats the levels of GLT-1 were at the same levels as in WT rats p | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | PDTC also increased the levels of astrocyte-specific glutamate transporter (GLT-1) GLT-1 | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | the spinal cords of untreated TG rats the levels of GLT-1 were decreased whereas in PDTC-treated TG rats the levels of | | |
| 17008387 | GLT-1 | GLT-1 | 1.0 | were decreased whereas in PDTC-treated TG rats the levels of GLT-1 were at the same levels as in WT rats ( | | |
| 17015226 | EAAT2 | EAAT2 | 2.8 | caspase-3 activation in glial cells proteolytically inactivates the glutamate transporter EAAT2 ( Boston-Howes et_amp_#xa0 al. 2006 | | |
| 17015226 | EAAT2 | EAAT2 | 2.8 | Since EAAT2 is selectively lost during the disease process and is considered | | |
| 17015226 | EAAT2 | EAAT2 | 2.8 | synaptic glutamate through the action of the glial glutamate transporter EAAT2 (also also referred to as GLT-1 in rodents | | |
| 17015226 | GLT-1 | GLT-1 | 2.8 | the glial glutamate transporter EAAT2 (also also referred to as GLT-1 in rodents | | |
| 17015226 | EAAT2 | EAAT2 | 2.8 | ALS patients ( Rothstein et_amp_#xa0 al. 1992 and levels of EAAT2 are reduced in the motor cortex and spinal cord of | | |
| 17015226 | EAAT2 | EAAT2 | 2.8 | for familial ALS in that hSOD1 G93A mice heterozygous for EAAT2 develop earlier-onset disease ( Pardo et_amp_#xa0 al. 2006 while drugs | | |
| 17015226 | EAAT2 | EAAT2 | 2.8 | disease ( Pardo et_amp_#xa0 al. 2006 while drugs that increase EAAT2 activity extend survival ( Ganel et_amp_#xa0 al. 2006 and Rothstein | | |
| 17015226 | EAAT2 | EAAT2 | 2.8 | Indeed screening of FDA-approved drugs for those that_amp_#xa0 could elevate EAAT2 activity has identified_amp_#xa0 a CNS-penetrating _amp_#x3b2 -lactam antibiotic ceftriaxone as_amp_#xa0 | | |
| 17015226 | EAAT2 | EAAT2 | 2.8 | activation in response to neuronal damage induces loss of the EAAT2 glutamate transporter reducing rapid recovery of synaptic glutamate and driving | | |
| 17015226 | EAAT2 | EAAT2 | 2.8 | Loss of EAAT2 glutamate transporters from astrocytes drives repetitive firing of glutamate receptors | | |
| 18464925 | GLT-1 | GLT-1 | 2.8 | agonist L-796 449 induced a concentration-dependent increase in glutamate transporter GLT-1 expression and 3 H glutamate uptake in rat astrocytes | | |
| 18464925 | GLT1 | GLT1 | 3.1 | identified six putative PPREs in the promoter region of GLT1/EAAT2 GLT1 EAAT2 gene suggesting GLT1/EAAT2 GLT1 EAAT2 glutamate transporter is a | | |
| 18464925 | EAAT2 | EAAT2 | 3.3 | six putative PPREs in the promoter region of GLT1/EAAT2 GLT1 EAAT2 gene suggesting GLT1/EAAT2 GLT1 EAAT2 glutamate transporter is a novel | | |
| 18464925 | GLT1 | GLT1 | 3.1 | the promoter region of GLT1/EAAT2 GLT1 EAAT2 gene suggesting GLT1/EAAT2 GLT1 EAAT2 glutamate transporter is a novel PPAR-_amp_#x003b3 target gene 56 | | |
| 18464925 | EAAT2 | EAAT2 | 3.3 | promoter region of GLT1/EAAT2 GLT1 EAAT2 gene suggesting GLT1/EAAT2 GLT1 EAAT2 glutamate transporter is a novel PPAR-_amp_#x003b3 target gene 56 | | |
| 18598679 | EAAT2 | EAAT2 | 1.0 | Corroborating this view are the elevated levels of EAAT2 after exposure to LPS ( Persson et al. 2005 and | | |
| 15210305 | excitatory amino acid transporter 2 | excitatory amino acid transporter 2 | 1.0 | for this reason the expression of glutamate receptors and of the excitatory amino acid transporter 2 eaat2 which is involved in the removal of glutamate from the synapse in spinal cord have been extensively investigated [ 92 and 107 ]. | | |
| 15572176 | glt 1 | glt 1 | 1.0 | g85r sod 1 mutation astrocytes display major morphological and functional changes characterized by the appearance of sod1 containing aggregates and decreased expression of glial glutamate transporter glt 1 [ 18 ]. | | |
| 15572176 | glt 1 | glt 1 | 1.0 | howland et al. [ 62 ] found that gliosis coincided with early vacuolization of the neuropil and with a striking focal loss of the glt 1 glutamate transporter in the ventral horn. | | |
| 15572176 | glt 1 | glt1 | 1.0 | many als patients have elevated glutamate levels in cerebrospinal fluid and a selective reduction of the astrocytic glutamate transporter eaat2 glt1 giving support to the excitotoxic hypothesis of motor neuron degeneration [ 107 ]. | | |
| 16179515 | excitatory amino acid transporter 2 | excitatory amino acid transporter 2 | 1.0 | however it did upregulate 3 genes unaffected by the presence of the g93a/sod1 mutation: glial fibrillary acidic protein gfap stroma derived factor 1 sdf 1 and excitatory amino acid transporter 2 eaat2 . | | |
| 17008387 | glt 1 | glt 1 | 1.0 | structions and immunostained using rabbit polyclonal anti proteasome 20s lmp7 dilution 1:1000; abcam cambridge uk rabbit polyclonal anti proteasome 20s x dilution 1:1000; abcam rabbit polyclonal anti glt 1 dilution 1:1000; calbiochem la jolla ca monoclonal anti beta actin dilution 1:4000 sigma or rabbit polyclonal anti ubiquitin antibodies dilution 1:1000; dakocytomation denmark a/s glostrup denmark an | | |
| 17008387 | glt 1 | glt 1 | 1.0 | the fact that pdtc treatment prevented the reduction of the glutamate transporter glt 1 a potential therapeutic target verified in numerous animal studies of als gurney et al. 1996 ; howland et al. 2002 and that pdtc treatment did not induce toxic side effects in the tg or wt rats the n | | |
| 17008387 | glt 1 | glt 1 | 1.0 | ducts in rat peripheral nerves calviello et al. 2005 beta lactams such as ceftriaxone which have been reported to be neuroprotective in models of als by increasing expression of glutamate transporter glt 1 rothstein et al. 2005 beta lactams because it significantly increases the expression of glt 1 and cu concentration in the spinal cord we hypothesize that even though beta lactams and pdtc might both | | |
| 17008387 | glt 1 | glt 1 | 1.0 | rothstein et al. 2005 beta lactams because it significantly increases the expression of glt 1 and cu concentration in the spinal cord we hypothesize that even though beta lactams and pdtc might both be able to modulate glt 1 and cu concentration only pdtc but not beta lactams inhibits immunop | | |
| 17008387 | glt 1 | glt 1 | 1.0 | and cu concentration in the spinal cord we hypothesize that even though beta lactams and pdtc might both be able to modulate glt 1 and cu concentration only pdtc but not beta lactams inhibits immunoproteasome because induction of immunoproteasome may be a rather selective characteristic for als models compared with models of isc | | |
| 17008387 | glt 1 | glt 1 | 1.0 | in summary we report that pdtc a multipotent drug providing protection in various animal models by inhibiting nf kappab acting as an antioxidant and activating akt gsk3 beta pathway also induces glt 1 a potential drug target in brain diseases. | | |
| 17008387 | glt 1 | glt 1 | 1.0 | pdtc led to decreased immunoproteasome levels and increased glt 1 levels in tg rats at the end stage whereas pdtc had no effect on the levels of constitutive proteasome immunoproteasome or glt 1 in wt rats. | | |
| 17008387 | glt 1 | glt 1 | 1.0 | pdtc also had an effect on the levels of astrocyte specific glutamate transporter glt 1 . | | |
| 17008387 | glt 1 | glt 1 | 1.0 | a and c in the spinal cords of untreated tg rats the levels of glt 1 were decreased whereas in pdtc treated tg rats the levels of glt 1 were at the same levels as in wt rats. p _lt_ 0.05 n = 5 results shown are mean _amp_#177; s.d. | | |
| 17008387 | glt 1 | glt 1 | 1.0 | the changes in immunoproteasome levels after pdtc treatment were not due to common reduction of astroglial functions because pdtc also increased the levels of astrocyte specific glutamate transporter glt 1 . | | |
| 17008387 | glt 1 | glt 1 | 1.0 | in the spinal cords of untreated tg rats the levels of glt 1 were decreased whereas in pdtc treated tg rats the levels of glt 1 were at the same levels as in wt rats fig 5 a and c . | | |
| 17015226 | glt 1 | glt 1 | 1.0 | ential partners of motor neurons providing them with trophic support and mediating rapid recovery of synaptic glutamate through the action of the glial glutamate transporter eaat2 also referred to as glt 1 in rodents . | | |
| 18464925 | glt 1 | glt 1 | 1.0 | in addition rosiglitazone and the non tzd agonist l 796 449 induced a concentration dependent increase in glutamate transporter glt 1 expression and [ 3 h] glutamate uptake in rat astrocytes. | | |
| 18464925 | glt 1 | glt1 | 1.0 | in addition the authors identified six putative ppres in the promoter region of glt1/eaat2 gene suggesting glt1/eaat2 glutamate transporter is a novel ppar _amp_#x003b3; target gene [ 56 ]. | | |